Experienced in Catecholaminergic Polymorphic Ventricular Tachycardia

Dr. Nabil Dib

Interventional Cardiology | Cardiology
Sjhmc Physician Services
500 W Thomas Rd, 680 Dhmg St Joseph's Pelvi, 
Phoenix, AZ 
Accepting New Patients
Experienced in Catecholaminergic Polymorphic Ventricular Tachycardia
Sjhmc Physician Services
500 W Thomas Rd, 680 Dhmg St Joseph's Pelvi, 
Phoenix, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nabil Dib is an Interventional Cardiologist and a Cardiologist in Phoenix, Arizona. Dr. Dib is rated as an Experienced provider by MediFind in the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. His top areas of expertise are Coronary Heart Disease, Atherosclerosis, Double Discordia, Heart Transplant, and Atherectomy. Dr. Dib is currently accepting new patients.

His clinical research consists of co-authoring 48 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Interventional Cardiology
Cardiology
Licenses
Internal Medicine in AZ
Hospital Affiliations
Mercy Gilbert Medical Center
St. Joseph's Hospital And Medical Center
Chandler Regional Medical Center
Languages Spoken
English
Arabic
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EMI Health
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

SJHMC PHYSICIAN SERVICES
500 W Thomas Rd, 680 Dhmg St Joseph's Pelvi, Phoenix, AZ 85013

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

RELIEVE-HF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure
RELIEVE-HF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2025
Intervention Type: Other, Device
Study Phase: Not Applicable
OSB Lead-AMPLATZER PFO Occluder New Enrollment PAS
OSB Lead-AMPLATZER PFO Occluder New Enrollment PAS
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Device
Study Phase: Not Applicable
Multicenter Randomized Assessment of the Firehawk™ Rapamycin TARGET Eluting Cobalt Chromium Coronary Stent System - North American Trial
Multicenter Randomized Assessment of the Firehawk™ Rapamycin TARGET Eluting Cobalt Chromium Coronary Stent System - North American Trial
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)
A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)
Enrollment Status: Terminated
Publish Date: January 09, 2024
Intervention Type: Other, Drug
Study Drug: ARRY-371797 (PF-07265803)
Study Phase: Phase 3
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions
Enrollment Status: Completed
Publish Date: October 30, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions.
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions.
Enrollment Status: Completed
Publish Date: October 11, 2023
Intervention Type: Device
Study Phase: Not Applicable
Mesenchymal Stromal Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome
Mesenchymal Stromal Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome
Enrollment Status: Terminated
Publish Date: April 25, 2022
Intervention Type: Biological, Drug
Study Drug: Remestemcel-L
Study Phase: Phase 3
Human Recombinant Fibroblast Growth Factor-1 (FGF-1), for the Treatment of Subjects With Severe Coronary Heart Disease, a Placebo Controlled, Double-blind, Dose-varying Study
Human Recombinant Fibroblast Growth Factor-1 (FGF-1), for the Treatment of Subjects With Severe Coronary Heart Disease, a Placebo Controlled, Double-blind, Dose-varying Study
Enrollment Status: Unknown
Publish Date: November 01, 2019
Intervention Type: Combination product
Study Drug: Human Recombinant Fibroblast Growth Factor-1
Study Phase: Phase 2
View 7 Less Clinical Trials

48 Total Publications

From the Hazards of Death to the Hazards of Indication Creep for TAVR.
From the Hazards of Death to the Hazards of Indication Creep for TAVR.
Journal: Journal of the American College of Cardiology
Published: May 19, 2025
Similar Doctors
Advanced in Catecholaminergic Polymorphic Ventricular Tachycardia
Dr. Joshua D. Waggoner
Interventional Cardiology | Cardiology
Advanced in Catecholaminergic Polymorphic Ventricular Tachycardia
Dr. Joshua D. Waggoner
Interventional Cardiology | Cardiology

Nassim Haddad MD PLLC

10101 N 92nd St, Suite 101, 
Scottsdale, AZ 
 (13.4 miles away)
480-747-6532
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joshua Waggoner is an Interventional Cardiologist and a Cardiologist in Scottsdale, Arizona. Dr. Waggoner is rated as an Advanced provider by MediFind in the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. His top areas of expertise are Catecholaminergic Polymorphic Ventricular Tachycardia, Ventricular Tachycardia, Angina, Aortic Valve Replacement, and Transcatheter Aortic Valve Replacement (TAVR). Dr. Waggoner is currently accepting new patients.

Distinguished in Catecholaminergic Polymorphic Ventricular Tachycardia
Dr. Marwan M. Bahu
Cardiac Electrophysiology | Cardiology
Distinguished in Catecholaminergic Polymorphic Ventricular Tachycardia
Dr. Marwan M. Bahu
Cardiac Electrophysiology | Cardiology

Vhs Outpatient Clinics Inc

1930 E Thomas Rd, 
Phoenix, AZ 
 (2.3 miles away)
602-532-1000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Marwan Bahu is a Cardiac Electrophysiologist and a Cardiologist in Phoenix, Arizona. Dr. Bahu is rated as a Distinguished provider by MediFind in the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. His top areas of expertise are Atrial Fibrillation, Ventricular Tachycardia, Catecholaminergic Polymorphic Ventricular Tachycardia, Cardiac Ablation, and Pacemaker Implantation. Dr. Bahu is currently accepting new patients.

Distinguished in Catecholaminergic Polymorphic Ventricular Tachycardia
Dr. Sudarone Thihalolipavan
Cardiac Electrophysiology | Cardiology
Distinguished in Catecholaminergic Polymorphic Ventricular Tachycardia
Dr. Sudarone Thihalolipavan
Cardiac Electrophysiology | Cardiology

Swarup LLC

1848 E Thomas Rd, Suite 100, 
Phoenix, AZ 
 (2.2 miles away)
602-456-2342
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sudarone Thihalolipavan is a Cardiac Electrophysiologist and a Cardiologist in Phoenix, Arizona. Dr. Thihalolipavan is rated as a Distinguished provider by MediFind in the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. His top areas of expertise are Atrial Fibrillation, Ectopic Heartbeat, Arrhythmias, Cardiac Ablation, and Pacemaker Implantation. Dr. Thihalolipavan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dib's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 45 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile